Tested drug for platinum-resistant ovarian cancer with bevacizumab
Treatments studied
Part of Cancer, Hormones & metabolism, Infections, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that cannot be fully removed by surgery.
- Your cancer type is high-grade serous (including certain mixed types), endometrioid, or clear-cell.
- You’ve already tried at least 3 rounds (“lines”) of cancer treatment, and the most recent treatment had imaging-confirmed progression.
- Your cancer is “platinum-resistant” or “platinum-refractory,” based on how soon it progressed after your last platinum dose (and you must have had at least 2 platinum doses in that last line).
- You previously received bevacizumab (or a similar biosimilar), and you can safely take bevacizumab and platinum medicines (carboplatin or cisplatin).
- Scans show at least one measurable tumor spot, and your blood/organ tests (kidney, liver, bone marrow, clotting) are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests a combination of four drugs for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this new combination can shrink tumors or slow the disease.
This study tests a new drug (BG-C9074) combined with a standard targeted therapy (bevacizumab) for women newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding this new drug can help shrink or control the cancer better than the standard approach alone.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.